Home›Diabetes & Endocrinology› Older age, longer diabetes duration, and higher HbA1c levels associate with sarcopenia in type 2 diabetes
Older age, longer diabetes duration, and higher HbA1c levels associate with sarcopenia in type 2 diabetesSeveral Factors Linked to Muscle Loss in Type 2 Diabetes
Frontiers in MedicinePublished September 11, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that older age, longer diabetes duration, and higher HbA1c levels are associated with sarcopenia in type 2 diabetes.
This meta-analysis evaluates the association between various clinical factors and sarcopenia in a population of 4,727 older patients with type 2 diabetes. The study synthesized data on factors including age, duration of diabetes, glycemic markers, and various metabolic and lifestyle indicators.
The analysis found that patients with sarcopenia were significantly older and had a longer duration of diabetes compared to those without. Additionally, patients with sarcopenia exhibited higher fasting blood glucose and higher HbA1c levels. Conversely, a negative association was observed with body mass index and hemoglobin levels. No statistically significant associations were found for male sex, total cholesterol, triglycerides, HDL-C, LDL-C, serum albumin, 25(OH)D, hypertension, smoking exposure, insulin therapy, or coronary/ischemic heart disease.
Several limitations were noted, including a cross-sectional study design, substantial inconsistency, and substantial heterogeneity. Furthermore, prediction intervals crossed the null value, and the certainty of evidence was low for HDL-C, hypertension, and insulin therapy, while it was very low for all other pooled outcomes. These findings may heighten clinical suspicion during guideline-based sarcopenia assessments, though they do not establish independent prediction or causality.
How this fits prior evidence
This meta-analysis addresses a gap in identifying clinical predictors of sarcopenia in patients with type 2 diabetes. While previous evidence highlighted that elastic-band resistance training improves HbA1c and fasting plasma glucose, and combined aerobic-resistance training provides superior metabolic benefits for obese patients with type 2 diabetes, this study focuses on the clinical profile of patients already presenting with sarcopenia. It identifies age, duration of diabetes, and HbA1c as significant factors, though the evidence certainty remains low.
Researchers analyzed data from over 4,700 older patients with type 2 diabetes to identify factors linked to sarcopenia, which is the loss of muscle mass and strength. The study looked at various clinical factors including age, blood sugar levels, and body mass index.
The findings showed that patients with muscle loss were significantly older and had lived with diabetes for a longer period. These patients also showed higher fasting blood glucose and HbA1c levels, as well as lower body mass index and lower hemoglobin levels. Other factors like cholesterol, smoking, and hypertension did not show a clear link to muscle loss in this specific analysis.
It is important to note that this study was a meta-analysis of cross-sectional data, which means it shows links rather than direct causes. The evidence for many of these links was considered low or very low in certainty. Because the data was inconsistent and varied, these findings are not intended to be used as a definitive screening tool, but they may help doctors stay alert to muscle loss in their patients.
What this means for you:
Older age and longer duration of type 2 diabetes are linked to muscle loss in some patients.
Common questions
What factors are linked to muscle loss in patients with type 2 diabetes?
The study found that patients with muscle loss were significantly older and had a longer duration of diabetes. These patients also had higher fasting blood glucose and HbA1c levels, and lower body mass index and hemoglobin levels. Other factors like cholesterol and smoking did not show a significant link.
Is this study a definitive way to diagnose muscle loss?
No, this study does not provide a validated screening tool or proof of cause. Because the evidence was of low to very low certainty and the data was inconsistent, these findings are meant to help doctors be more aware of muscle loss during routine checkups.
Who was included in this study?
The study included a total of 4,727 older patients who were diagnosed with type 2 diabetes. The researchers looked at their age, blood sugar levels, body mass index, and other clinical factors to see how they related to muscle loss.
Background and aimsSarcopenia is a common geriatric syndrome that substantially impairs physical function, mobility, and quality of life in older patients with type 2 diabetes mellitus. However, evidence regarding factors associated with sarcopenia in this population remains fragmented and inconsistent, and previous studies have often included mixed-age populations or provided limited quantitative synthesis specifically focused on older adults. Therefore, this systematic review and meta-analysis aimed to comprehensively identify and quantify the associations between clinical factors and sarcopenia in older patients with type 2 diabetes mellitus, thereby providing age-specific evidence for clinical assessment, early identification, and individualized management.MethodsRelevant studies examining factors associated with sarcopenia in older patients with type 2 diabetes mellitus were systematically searched in six databases: PubMed, Web of Science, Embase, the Cochrane Library, CNKI, and Wanfang Data. The search covered the period from database inception to January 2026. Study characteristics, participant characteristics, potential associated factors, and sarcopenia-related outcomes were extracted. The methodological quality of the included cross-sectional studies was assessed using the AHRQ checklist. Meta-analyses were conducted using Review Manager version 5.3. Continuous variables were pooled using mean differences or standardized mean differences, and dichotomous variables were pooled using odds ratios. Publication bias and small-study effects were assessed using funnel plots and Egger’s regression test when at least 10 studies were available for a given outcome. For outcomes with substantial heterogeneity, REML-based 95% prediction intervals and exploratory univariable meta-regression analyses were conducted when sufficient data were available. The certainty of evidence for each pooled outcome was assessed using the GRADE approach.ResultsA total of 19 cross-sectional studies involving 4,727 older patients with type 2 diabetes mellitus were included. The included studies were of moderate to high methodological quality, with no low-quality studies identified. Sarcopenia was diagnosed using different criteria, including the Asian Working Group for Sarcopenia 2014 criteria, the AWGS 2019 criteria, the European Working Group on Sarcopenia in Older People criteria, and the revised EWGSOP2 criteria. Meta-analysis showed that patients with sarcopenia were significantly older than those without sarcopenia, and had a longer duration of diabetes, higher fasting blood glucose levels, higher HbA1c levels, lower body mass index, and lower hemoglobin levels. No statistically significant associations were observed for male sex, total cholesterol, triglycerides, HDL-C, LDL-C, serum albumin, 25(OH)D, hypertension, smoking exposure, insulin therapy, or coronary/ischemic heart disease. Although sensitivity analyses generally supported the directional stability of the main findings, substantial heterogeneity remained for several outcomes, and all REML-based 95% prediction intervals crossed the null value. Exploratory meta-regression identified geographic region as a significant moderator only for HbA1c. Egger’s tests did not indicate statistically significant small-study effects for outcomes with sufficient studies. The certainty of evidence was rated as low for HDL-C, hypertension, and insulin therapy and as very low for all other pooled outcomes, primarily because of the cross-sectional study design, substantial inconsistency, and imprecision.ConclusionIn conclusion, older age, lower BMI, longer diabetes duration, higher fasting blood glucose, higher HbA1c, and lower hemoglobin levels were associated with sarcopenia in older patients with type 2 diabetes mellitus. However, the certainty of evidence was low to very low, and substantial heterogeneity and prediction intervals crossing the null value indicate that the magnitude and presence of these associations may vary across populations and clinical settings. These findings may heighten clinical suspicion during guideline-based sarcopenia assessment but should not be regarded as evidence of independent prediction, validated screening thresholds, or causality. Future prospective studies with standardized measurements and comprehensive adjustment for confounders are required.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420261301123.
